Question 1

What is retatrutide?

Accepted Answer

Retatrutide (LY3437943) is an investigational drug developed by Eli Lilly. It is a once-weekly subcutaneous injection that activates three hormone receptors: GLP-1, GIP, and glucagon. This triple-receptor mechanism distinguishes it from approved drugs like semaglutide and tirzepatide.

Question 2

Is retatrutide FDA approved?

Accepted Answer

No. As of September 2026, retatrutide is not approved by the FDA for any indication. It remains an investigational drug in Phase 3 clinical development.

Question 3

Who makes retatrutide?

Accepted Answer

Retatrutide is being developed by Eli Lilly and Company, which also developed tirzepatide (Mounjaro/Zepbound). Lilly is sponsoring the TRIUMPH Phase 3 clinical trial program.

Question 4

How does retatrutide work?

Accepted Answer

Retatrutide activates three receptors: GLP-1 (reduces appetite, slows gastric emptying), GIP (amplifies insulin secretion), and glucagon (increases energy expenditure). The triple combination is hypothesized to produce greater weight loss than single or dual agonists.

Question 5

What is a triple agonist?

Accepted Answer

A triple agonist activates three distinct receptor types. Retatrutide activates GLP-1, GIP, and glucagon receptors. This contrasts with GLP-1 single agonists (semaglutide) and dual GLP-1/GIP agonists (tirzepatide).

Question 6

Why is retatrutide called a triple agonist?

Accepted Answer

Retatrutide simultaneously activates three distinct hormone receptors: GIP, GLP-1, and glucagon. The informal nickname "GLP-3" is not a recognized scientific or regulatory classification.

Question 7

What does GIP do?

Accepted Answer

GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone that amplifies insulin secretion in a glucose-dependent manner and plays a role in fat metabolism. Retatrutide activates the GIP receptor as one of its three mechanisms.

Question 8

What does glucagon do, and why does retatrutide target it?

Accepted Answer

Glucagon raises blood glucose and increases energy expenditure. Retatrutide's glucagon receptor agonism is hypothesized to increase metabolic rate and reduce liver fat — effects beyond what GLP-1 and GIP agonism alone can achieve.

Question 9

What is the difference between a single, dual, and triple receptor agonist?

Accepted Answer

Single agonists activate one receptor (e.g., semaglutide: GLP-1 only). Dual agonists activate two (e.g., tirzepatide: GLP-1 + GIP). Triple agonists activate three (e.g., retatrutide: GLP-1 + GIP + glucagon).

Question 10

What is known about retatrutide and liver fat?

Accepted Answer

A Phase 2a substudy published in Nature Medicine (2024) found significant reductions in liver fat content (MASLD) with retatrutide. Phase 3 liver-specific data are pending.

Question 11

How much weight was lost in published trials?

Accepted Answer

Phase 2 (NEJM 2023): 24.2% mean weight loss at 48 weeks (12 mg). TRIUMPH-1 Phase 3 topline (May 2026): 28.3% at 80 weeks (12 mg). TRIUMPH-2 topline (July 2026): 20.8% at 12 mg. Phase 3 results are topline only; peer-reviewed publication is pending.

Question 12

What is TRIUMPH-1?

Accepted Answer

TRIUMPH-1 (NCT05929066) is the pivotal Phase 3 obesity trial. Topline results announced May 21, 2026 showed 28.3% mean body weight reduction at 80 weeks with 12 mg retatrutide.

Question 13

What did TRIUMPH-1 find?

Accepted Answer

TRIUMPH-1 topline results showed 28.3% (12 mg), 25.9% (9 mg), and 19.0% (4 mg) mean body weight reduction at 80 weeks. An extension population with BMI ≥35 showed up to 30.3% at 104 weeks.

Question 14

What is TRIUMPH-2?

Accepted Answer

TRIUMPH-2 (NCT05929079) is a Phase 3 trial in adults with obesity and type 2 diabetes. Topline results (July 23, 2026): 12 mg −20.8%, 9 mg −19.1%, 4 mg −12.7%, placebo −4.0% body weight change.

Question 15

What is TRIUMPH-3?

Accepted Answer

TRIUMPH-3 (NCT05882045) is a Phase 3 trial in adults with established cardiovascular disease and severe obesity. Topline results were announced July 23, 2026.

Question 16

What is TRIUMPH-Outcomes?

Accepted Answer

TRIUMPH-Outcomes (NCT06383390) is a long-term cardiovascular and kidney outcomes trial evaluating retatrutide in adults with obesity. It is an event-driven trial expected to run for several years.

Question 17

What is TRANSCEND-T2D?

Accepted Answer

TRANSCEND-T2D-2 (NCT06260722) compares retatrutide with semaglutide in type 2 diabetes. TRANSCEND-T2D-3 (NCT06297603) evaluates retatrutide in type 2 diabetes with renal impairment.

Question 18

What does Phase 3 mean for retatrutide?

Accepted Answer

Phase 3 trials are large-scale, randomized, controlled studies required before FDA submission. For retatrutide, Phase 3 is the TRIUMPH and TRANSCEND programs across multiple populations and indications.

Question 19

Has Eli Lilly submitted retatrutide to the FDA?

Accepted Answer

As of September 2026, no. Eli Lilly announced plans for a Q1 2027 regulatory submission following TRIUMPH-1 (May 2026) and TRIUMPH-2/3 (July 2026) topline results.

Question 20

What is a New Drug Application (NDA)?

Accepted Answer

An NDA is the formal submission a pharmaceutical company makes to the FDA requesting approval to market a new drug. It includes all clinical trial data, proposed labeling, manufacturing information, and safety data.

Question 21

When could an FDA decision on retatrutide occur?

Accepted Answer

If Lilly submits in Q1 2027 and receives standard FDA review (10–12 months), a decision could occur in late 2027 or early 2028. Under Priority Review (6 months), earlier. Approval is not guaranteed.

Question 22

Where was retatrutide research published?

Accepted Answer

Primary publications: Phase 2 obesity trial in NEJM (2023); Phase 1b T2D study on PubMed (2022); Phase 2a liver fat substudy in Nature Medicine (2024); structural biology in Cell Discovery (2024). Phase 3 topline results are not yet peer-reviewed.

Question 23

Is retatrutide research published in the New England Journal of Medicine?

Accepted Answer

Yes. Jastreboff AM et al., "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial," was published in NEJM in June 2023 (DOI: 10.1056/NEJMoa2301972).

Question 24

Is retatrutide listed on PubMed?

Accepted Answer

Yes. Multiple retatrutide studies are indexed on PubMed. The Phase 1b T2D study is at PubMed ID 36354040. Search PubMed for "retatrutide" to find all indexed publications.

Question 25

What is the difference between topline results and peer-reviewed results?

Accepted Answer

Topline results are summary findings announced by the sponsor before independent scientific review. Peer-reviewed results are published in a journal after expert review of the complete dataset. TRIUMPH Phase 3 results are currently topline only.

Question 26

What side effects were reported in trials?

Accepted Answer

The most common side effects were gastrointestinal: nausea (~45% at 12 mg), vomiting (~25%), diarrhea (~20%), and constipation (~15%). These were generally dose-dependent and most frequent during dose escalation. Trial protocols include a class-level MTC/MEN2 precaution based on rodent data.

Question 27

What are the most common side effects of retatrutide?

Accepted Answer

The most common side effects were gastrointestinal: nausea (~45% at 12 mg), vomiting (~25%), diarrhea (~20%), and constipation (~15%). Injection site reactions were reported in ~20–30% of participants. All were dose-dependent and most frequent during dose escalation.

Question 28

Do retatrutide side effects go away over time?

Accepted Answer

GI side effects are most pronounced during dose escalation and improve significantly at stable maintenance dose. Injection site reactions typically resolve within days. Heart rate elevation tends to persist at stable dose. Slow dose escalation is the primary mitigation strategy.

Question 29

What are the most serious side effects of retatrutide?

Accepted Answer

The most clinically significant risks are pancreatitis (class effect of GLP-1 agonists), gallbladder disease, and the theoretical thyroid C-cell tumor risk (rodent data; human relevance unestablished). Retatrutide has no FDA-approved prescribing label; trial protocols exclude patients with personal or family history of MTC or MEN2 as a class-level precaution. Serious adverse events were reported in ~8% of Phase 2 participants.

Question 30

Are retatrutide's side effects worse than tirzepatide or semaglutide?

Accepted Answer

Based on Phase 2 data, retatrutide at 12 mg has higher GI adverse event rates (~45% nausea) and discontinuation (~16%) than tirzepatide 15 mg (~25–30% nausea, ~8% discontinuation) or semaglutide 2.4 mg (~20% nausea, ~7% discontinuation). Cross-trial comparisons are indirect.

Question 31

Does retatrutide increase heart rate?

Accepted Answer

Yes. Retatrutide produces a mean resting heart rate increase of approximately +4–7 bpm at 12 mg — larger than semaglutide (+1–3 bpm) or tirzepatide (+2–4 bpm), likely due to glucagon receptor agonism. Patients with pre-existing cardiac conditions should discuss this with a cardiologist.

Question 32

How many people stopped taking retatrutide due to side effects?

Accepted Answer

Discontinuation due to adverse events in Phase 2 was dose-dependent: ~3% (1 mg), ~7% (4 mg), ~11% (8 mg), ~16% (12 mg). The majority of discontinuations were GI-related.

Question 33

Does retatrutide cause pancreatitis?

Accepted Answer

Pancreatitis is a known class effect of GLP-1 receptor agonists. Retatrutide carries a theoretical risk. Persistent severe abdominal pain requires immediate evaluation. Retatrutide should be discontinued if pancreatitis is confirmed.

Question 34

Does retatrutide cause thyroid cancer?

Accepted Answer

GLP-1 agonists carry an FDA class warning regarding thyroid C-cell tumors based on rodent studies. Human relevance is unestablished. Retatrutide has no FDA-approved prescribing label; trial protocols exclude patients with personal or family history of medullary thyroid carcinoma (MTC) or MEN2 as a class-level precaution.

Question 35

How can nausea from retatrutide be managed?

Accepted Answer

Slow dose escalation (4-week intervals per TRIUMPH protocol) is the primary strategy. Additional approaches: smaller lower-fat meals, staying hydrated, timing injections, and dose reduction for intolerable symptoms. Nausea typically improves at stable maintenance dose.

Question 36

Does retatrutide affect the gallbladder?

Accepted Answer

Yes. Gallbladder disease (cholelithiasis, cholecystitis) was reported in Phase 2. Both rapid weight loss and GLP-1 agonism are associated with gallstone formation. Patients with prior gallbladder disease should discuss prophylactic strategies with their physician.

Question 37

Does retatrutide cause low blood sugar (hypoglycemia)?

Accepted Answer

Retatrutide alone has low hypoglycemia risk in non-diabetic individuals due to glucose-dependent insulin stimulation. Risk increases substantially when combined with insulin secretagogues or exogenous insulin. Patients on these medications should have doses reviewed before initiating.

Question 38

What injection site reactions does retatrutide cause?

Accepted Answer

Injection site reactions were reported in ~20–30% of participants: pain/tenderness (~20–25%), erythema (~10–15%), and nodules/induration (~5–10%). All are generally mild and self-limiting. Rotating injection sites and allowing medication to reach room temperature reduce local reactions.

Question 39

Can you buy retatrutide?

Accepted Answer

No. Retatrutide is not approved for sale or prescription anywhere as of September 2026. It is available only to participants in authorized clinical trials.

Question 40

Can retatrutide legally be compounded?

Accepted Answer

No. Retatrutide does not currently satisfy the federal requirements that would allow it to be used as a bulk drug substance for compounding under 503A or 503B frameworks. It has no approved NDA and is not on any FDA shortage list or bulk drug substance list.

Question 41

Is retatrutide the same as tirzepatide?

Accepted Answer

No. Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1/GIP agonist approved by the FDA. Retatrutide adds glucagon receptor agonism as a third mechanism.

Question 42

How does retatrutide compare to semaglutide?

Accepted Answer

Semaglutide (Ozempic/Wegovy) is a GLP-1 single agonist. Retatrutide adds GIP and glucagon receptor activation. Phase 2 data suggests substantially greater weight loss with retatrutide, though cross-trial comparisons have important limitations.

Retatrutide FAQ